Global Considerations in Human Immunodeficiency Virus-Associated Respiratory Disease

Abstract

Respiratory tract infection, particularly tuberculosis, is a major cause of mortality among human immunodeficiency virus (HIV)-infected individuals. Antiretroviral therapy (ART) has resulted in a dramatic increase in survival, although coverage of HIV treatment remains low in many parts of the world. There is a concurrent growing burden of chronic noninfectious respiratory disease as a result of increased survival. Many risk factors associated with the development of respiratory disease, such as cigarette smoking and intravenous drug use, are overrepresented among people living with HIV. In addition, there is emerging evidence that HIV infection may directly cause or accelerate the course of chronic lung disease. This review summarizes the clinical spectrum and epidemiology of respiratory tract infections and noninfectious pulmonary pathologies, and factors that explain the global variation in HIV-associated respiratory disease. The potential for enhancing diagnoses of noninfective chronic conditions through the use of clinical algorithms is discussed. We also consider issues in assessment and management of HIV-related respiratory disease in view of the increasing global scale up of ART.

Keywords

lung - HIV - respiratory tract Infection - chronic lung disease - developing countries - algorithms

• References

• 1 UNAIDS. How AIDS changed everything—MDG6: 15 years, 15 lessons of hope from the AIDS response. Available at: http://www.unaids.org/en/resources/documents/2015/MDG6_15years-15lessonsfromtheAIDSresponse . Accessed August 26, 2015
• 2 World Health Organization. The top 10 causes of death: Fact sheet no. 310. Available at: http://www.who.int/mediacentre/factsheets/fs310/en/ . Accessed August 26, 2015
• 3 (UNAIDS) JUNPoHA. The Gap Report. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2014. . Available at: http://www.unaids.org/en/resources/documents/2014/20140716_UNAIDS_gap_report . Accessed February 6, 2016
• 4 Bor J, Herbst AJ, Newell ML, Bärnighausen T. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science 2013; 339 (6122) 961-965
• 5 Bates M, Mudenda V, Mwaba P, Zumla A. Deaths due to respiratory tract infections in Africa: a review of autopsy studies. Curr Opin Pulm Med 2013; 19 (3) 229-237
• 6 Ferrand RA, Corbett EL, Wood R , et al. AIDS among older children and adolescents in Southern Africa: projecting the time course and magnitude of the epidemic. AIDS 2009; 23 (15) 2039-2046
• 7 Allwood BW, Myer L, Bateman ED. A systematic review of the association between pulmonary tuberculosis and the development of chronic airflow obstruction in adults. Respiration 2013; 86 (1) 76-85
• 8 Chalmers JD, Hill AT. Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. Mol Immunol 2013; 55 (1) 27-34
• 9 Morris A, George MP, Crothers K , et al; Lung HIV Study. HIV and chronic obstructive pulmonary disease: is it worse and why?. Proc Am Thorac Soc 2011; 8 (3) 320-325
• 10 Drummond MB, Merlo CA, Astemborski J , et al. The effect of HIV infection on longitudinal lung function decline among IDUs: a prospective cohort. AIDS 2013; 27 (8) 1303-1311
• 11 Cole SR, Chu H, Allison PD, Gange SJ. Combined analysis of retrospective and prospective occurrences in cohort studies: HIV-1 serostatus and incident pneumonia. Int J Epidemiol 2006; 35 (6) 1442-1446
• 12 Feikin DR, Njenga MK, Bigogo G , et al. Etiology and Incidence of viral and bacterial acute respiratory illness among older children and adults in rural western Kenya, 2007-2010. PLoS ONE 2012; 7 (8) e43656
• 13 Cohen C, Walaza S, Moyes J , et al. Epidemiology of severe acute respiratory illness (SARI) among adults and children aged ≥5 years in a high HIV-prevalence setting, 2009-2012. PLoS ONE 2015; 10 (2) e0117716
• 14 Iwuji CC, Mayanja BN, Weiss HA , et al. Morbidity in HIV-1-infected individuals before and after the introduction of antiretroviral therapy: a longitudinal study of a population-based cohort in Uganda. HIV Med 2011; 12 (9) 553-561
• 15 Gray DM, Zar HJ. Community-acquired pneumonia in HIV-infected children: a global perspective. Curr Opin Pulm Med 2010; 16 (3) 208-216
• 16 Benito N, Moreno A, Miro JM, Torres A. Pulmonary infections in HIV-infected patients: an update in the 21st century. Eur Respir J 2012; 39 (3) 730-745
• 17 Laxminarayan R, Duse A, Wattal C , et al. Antibiotic resistance-the need for global solutions. Lancet Infect Dis 2013; 13 (12) 1057-1098
• 18 Charalambous S, Day JH, Fielding K, De Cock KM, Churchyard GJ, Corbett EL. HIV infection and chronic chest disease as risk factors for bacterial pneumonia: a case-control study. AIDS 2003; 17 (10) 1531-1537
• 19 Azziz-Baumgartner E, Alamgir AS, Rahman M , et al. Incidence of influenza-like illness and severe acute respiratory infection during three influenza seasons in Bangladesh, 2008-2010. Bull World Health Organ 2012; 90 (1) 12-19
• 20 Marston BJ, Plouffe JF, File Jr TM , et al; The Community-Based Pneumonia Incidence Study Group. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. Arch Intern Med 1997; 157 (15) 1709-1718
• 21 Olsen SJ, Laosiritaworn Y, Siasiriwattana S, Chunsuttiwat S, Dowell SF. The incidence of pneumonia in rural Thailand. Int J Infect Dis 2006; 10 (6) 439-445
• 22 Tornheim JA, Manya AS, Oyando N, Kabaka S, Breiman RF, Feikin DR. The epidemiology of hospitalized pneumonia in rural Kenya: the potential of surveillance data in setting public health priorities. Int J Infect Dis 2007; 11 (6) 536-543
• 23 Malinis M, Myers J, Bordon J , et al. Clinical outcomes of HIV-infected patients hospitalized with bacterial community-acquired pneumonia. Int J Infect Dis 2010; 14 (1) e22-e27
• 24 Feldman C, Anderson R. HIV-associated bacterial pneumonia. Clin Chest Med 2013; 34 (2) 205-216
• 25 Scott JA, Hall AJ, Muyodi C , et al. Aetiology, outcome, and risk factors for mortality among adults with acute pneumonia in Kenya. Lancet 2000; 355 (9211) 1225-1230
• 26 Theodoratou E, McAllister DA, Reed C , et al. Global, regional, and national estimates of pneumonia burden in HIV-infected children in 2010: a meta-analysis and modelling study. Lancet Infect Dis 2014; 14 (12) 1250-1258
• 27 Falade AG, Ayede AI. Epidemiology, aetiology and management of childhood acute community-acquired pneumonia in developing countries—a review. Afr J Med Med Sci 2011; 40 (4) 293-308
• 28 Woodhead M. Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. Eur Respir J Suppl 2002; 36: 20s-27s
• 29 Peto L, Nadjm B, Horby P , et al. The bacterial aetiology of adult community-acquired pneumonia in Asia: a systematic review. Trans R Soc Trop Med Hyg 2014; 108 (6) 326-337
• 30 Wiersinga WJ, Currie BJ, Peacock SJ. Melioidosis. N Engl J Med 2012; 367 (11) 1035-1044
• 31 Fischer II WA, Gong M, Bhagwanjee S, Sevransky J. Global burden of influenza as a cause of cardiopulmonary morbidity and mortality. Glob Heart 2014; 9 (3) 325-336
• 32 Cohen C, Moyes J, Tempia S , et al. Mortality amongst patients with influenza-associated severe acute respiratory illness, South Africa, 2009-2013. PLoS ONE 2015; 10 (3) e0118884
• 33 Fischer GB, Sarria EE, Mattiello R, Mocelin HT, Castro-Rodriguez JA. Post infectious bronchiolitis obliterans in children. Paediatr Respir Rev 2010; 11 (4) 233-239
• 34 Hammitt LL, Kazungu S, Morpeth SC , et al. A preliminary study of pneumonia etiology among hospitalized children in Kenya. Clin Infect Dis 2012; 54 (Suppl. 02) S190-S199
• 35 Kelly MS, Smieja M, Luinstra K , et al. Association of respiratory viruses with outcomes of severe childhood pneumonia in Botswana. PLoS ONE 2015; 10 (5) e0126593
• 36 Nunes MC, Kuschner Z, Rabede Z , et al. Clinical epidemiology of bocavirus, rhinovirus, two polyomaviruses and four coronaviruses in HIV-infected and HIV-uninfected South African children. PLoS ONE 2014; 9 (2) e86448
• 37 WHO. Global Tuberculosis Report 2014. Geneva, Switzerland: World Health Organization; 2014
• 38 Munthali L, Khan PY, Mwaungulu NJ , et al. The effect of HIV and antiretroviral therapy on characteristics of pulmonary tuberculosis in northern Malawi: a cross-sectional study. BMC Infect Dis 2014; 14: 107
• 39 Stone VE. Quality primary care for HIV/AIDS: how much HIV/AIDS experience is enough?. J Gen Intern Med 2003; 18 (2) 157-158
• 40 Zwang J, Garenne M, Kahn K, Collinson M, Tollman SM. Trends in mortality from pulmonary tuberculosis and HIV/AIDS co-infection in rural South Africa (Agincourt). Trans R Soc Trop Med Hyg 2007; 101 (9) 893-898
• 41 Haar CH, Cobelens FG, Kalisvaart NA, van Gerven PJ, van der Have JJ. HIV-related mortality among tuberculosis patients in The Netherlands, 1993-2001. Int J Tuberc Lung Dis 2007; 11 (9) 1038-1041
• 42 Duarte EC, Bierrenbach AL, Barbosa da Silva Jr J, Tauil PL, de Fátima Duarte E. Factors associated with deaths among pulmonary tuberculosis patients: a case-control study with secondary data. J Epidemiol Community Health 2009; 63 (3) 233-238
• 43 Ciglenecki I, Glynn JR, Mwinga A , et al. Population differences in death rates in HIV-positive patients with tuberculosis. Int J Tuberc Lung Dis 2007; 11 (10) 1121-1128
• 44 Cain KP, Kanara N, Laserson KF , et al. The epidemiology of HIV-associated tuberculosis in rural Cambodia. Int J Tuberc Lung Dis 2007; 11 (9) 1008-1013
• 45 Lawn SD, Churchyard G. Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS 2009; 4 (4) 325-333
• 46 Gupta RK, Lucas SB, Fielding KL, Lawn SD. Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. AIDS 2015; 29 (15) 1987-2002
• 47 Martinson NA, Karstaedt A, Venter WD , et al. Causes of death in hospitalized adults with a premortem diagnosis of tuberculosis: an autopsy study. AIDS 2007; 21 (15) 2043-2050
• 48 Wong EB, Omar T, Setlhako GJ , et al. Causes of death on antiretroviral therapy: a post-mortem study from South Africa. PLoS ONE 2012; 7 (10) e47542
• 49 Lawn SD, Meintjes G, McIlleron H, Harries AD, Wood R. Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review. BMC Med 2013; 11: 253
• 50 Lawn SD, Wood R. When should antiretroviral treatment be started in patients with HIV-associated tuberculosis in South Africa?. S Afr Med J 2007; 97 (6) 412 , 414–415
• 51 Lowe DM, Rangaka MX, Gordon F, James CD, Miller RF. Pneumocystis jirovecii pneumonia in tropical and low and middle income countries: a systematic review and meta-regression. PLoS ONE 2013; 8 (8) e69969
• 52 Fei MW, Kim EJ, Sant CA , et al. Predicting mortality from HIV-associated Pneumocystis pneumonia at illness presentation: an observational cohort study. Thorax 2009; 64 (12) 1070-1076
• 53 Shirley RM, Baddley JW. Cryptococcal lung disease. Curr Opin Pulm Med 2009; 15 (3) 254-260
• 54 Jarvis JN, Bicanic T, Loyse A , et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes. Clin Infect Dis 2014; 58 (5) 736-745
• 55 Hage CA, Knox KS, Davis TE, Wheat LJ. Antigen detection in bronchoalveolar lavage fluid for diagnosis of fungal pneumonia. Curr Opin Pulm Med 2011; 17 (3) 167-171
• 56 Nacher M, Adenis A, Adriouch L , et al. What is AIDS in the Amazon and the Guianas? Establishing the burden of disseminated histoplasmosis. Am J Trop Med Hyg 2011; 84 (2) 239-240
• 57 Adenis AA, Aznar C, Couppié P. Histoplasmosis in HIV-Infected Patients: A Review of New Developments and Remaining Gaps. Curr Trop Med Rep 2014; 1 (X) 119-128
• 58 Crothers K, Huang L, Goulet JL , et al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med 2011; 183 (3) 388-395
• 59 Crothers K, McGinnis K, Kleerup E , et al. HIV infection is associated with reduced pulmonary diffusing capacity. J Acquir Immune Defic Syndr 2013; 64 (3) 271-278
• 60 Drummond MB, Huang L, Diaz PT , et al. Factors associated with abnormal spirometry among HIV-infected individuals. AIDS 2015; 29 (13) 1691-1700
• 61 Drummond MB, Kirk GD. HIV-associated obstructive lung diseases: insights and implications for the clinician. Lancet Respir Med 2014; 2 (7) 583-592
• 62 Gingo MR, Morris A, Crothers K. Human immunodeficiency virus-associated obstructive lung diseases. Clin Chest Med 2013; 34 (2) 273-282
• 63 Scourfield AT, Doffman SR, Miller RF. Chronic obstructive pulmonary disease in patients with HIV: an emerging problem. Br J Hosp Med (Lond) 2014; 75 (12) 678-684
• 64 Attia EF, Akgün KM, Wongtrakool C , et al. Increased risk of radiographic emphysema in HIV is associated with elevated soluble CD14 and nadir CD4. Chest 2014; 146 (6) 1543-1553
• 65 Buist AS, Vollmer WM, Sullivan SD , et al. The Burden of Obstructive Lung Disease Initiative (BOLD): rationale and design. COPD 2005; 2 (2) 277-283
• 66 van Gemert F, Kirenga B, Chavannes N , et al. Prevalence of chronic obstructive pulmonary disease and associated risk factors in Uganda (FRESH AIR Uganda): a prospective cross-sectional observational study. Lancet Glob Health 2015; 3 (1) e44-e51
• 67 Fang X, Wang X, Bai C. COPD in China: the burden and importance of proper management. Chest 2011; 139 (4) 920-929
• 68 Jindal SK, Aggarwal AN, Gupta D , et al. Indian study on epidemiology of asthma, respiratory symptoms and chronic bronchitis in adults (INSEARCH). Int J Tuberc Lung Dis 2012; 16 (9) 1270-1277
• 69 Tan WC, Ng TP. COPD in Asia: where East meets West. Chest 2008; 133 (2) 517-527
• 70 Nakamura H, Tateyama M, Tasato D , et al. The prevalence of airway obstruction among Japanese HIV-positive male patients compared with general population; a case-control study of single center analysis. J Infect Chemother 2014; 20 (6) 361-364
• 71 Pefura-Yone EW, Fodjeu G, Kengne AP, Roche N, Kuaban C. Prevalence and determinants of chronic obstructive pulmonary disease in HIV infected patients in an African country with low level of tobacco smoking. Respir Med 2015; 109 (2) 247-254
• 72 McShane PJ, Naureckas ET, Tino G, Strek ME. Non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2013; 188 (6) 647-656
• 73 Clausen E, Wittman C, Gingo M , et al. Chest computed tomography findings in HIV-infected individuals in the era of antiretroviral therapy. PLoS ONE 2014; 9 (11) e112237
• 74 Zona S, Santoro A, Besutti G , et al. Burden of subclinical heart and lung disease detected on thoracic CT scans of HIV patients on HAART. J Int AIDS Soc 2014; 17 (4) (Suppl. 03) 19716
• 75 Pasteur MC, Bilton D, Hill AT ; British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010; 65 (Suppl. 01) i1-i58
• 76 Metcalfe JZ, Mason P, Mungofa S, Sandy C, Hopewell PC. Empiric tuberculosis treatment in retreatment patients in high HIV/tuberculosis-burden settings. Lancet Infect Dis 2014; 14 (9) 794-795
• 77 Masekela R, Anderson R, Moodley T , et al. HIV-related bronchiectasis in children: an emerging spectre in high tuberculosis burden areas. Int J Tuberc Lung Dis 2012; 16 (1) 114-119
• 78 Zar HJ. Chronic lung disease in human immunodeficiency virus (HIV) infected children. Pediatr Pulmonol 2008; 43 (1) 1-10
• 79 Mwalukomo T, Rylance SJ, Webb EL , et al. Clinical Characteristics and Lung Function in Older Children Vertically Infected With Human Immunodeficiency Virus in Malawi. J Pediatric Infect Dis Soc 2015;
• 80 Lloyd S, Taylor NK, Koumans E , et al. Prevalence of and risk factors for chronic lung disease among HIV-infected children. Poster presented at: 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 19–22, 2015; Vancouver, Canada
• 81 Pitcher RD, Lombard CJ, Cotton MF, Beningfield SJ, Workman L, Zar HJ. Chest radiographic abnormalities in HIV-infected African children: a longitudinal study. Thorax 2015; 70 (9) 840-846
• 82 Rylance J, Desai S , et al. Chronic respiratory ill-health in children with vertically acquired HIV: clinical features and lung function. Poster presented at: 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 19–22, 2015; Vancouver, Canada
• 83 Ferrand RA, Desai SR, Hopkins C , et al. Chronic lung disease in adolescents with delayed diagnosis of vertically acquired HIV infection. Clin Infect Dis 2012; 55 (1) 145-152
• 84 Stocks J, Hislop A, Sonnappa S. Early lung development: lifelong effect on respiratory health and disease. Lancet Respir Med 2013; 1 (9) 728-742
• 85 Doffman SR, Miller RF. Interstitial lung disease in HIV. Clin Chest Med 2013; 34 (2) 293-306
• 86 Moitra S, Puri R, Paul D, Huang YC. Global perspectives of emerging occupational and environmental lung diseases. Curr Opin Pulm Med 2015; 21 (2) 114-120
• 87 Corbett EL, Churchyard GJ, Clayton TC , et al. HIV infection and silicosis: the impact of two potent risk factors on the incidence of mycobacterial disease in South African miners. AIDS 2000; 14 (17) 2759-2768
• 88 Jeena PM, Coovadia HM, Thula SA, Blythe D, Buckels NJ, Chetty R. Persistent and chronic lung disease in HIV-1 infected and uninfected African children. AIDS 1998; 12 (10) 1185-1193
• 89 Sharland M, Gibb DM, Holland F. Respiratory morbidity from lymphocytic interstitial pneumonitis (LIP) in vertically acquired HIV infection. Arch Dis Child 1997; 76 (4) 334-336
• 90 Barnett CF, Hsue PY. Human immunodeficiency virus-associated pulmonary arterial hypertension. Clin Chest Med 2013; 34 (2) 283-292
• 91 Hakim JG, Matenga JA, Siziya S. Myocardial dysfunction in human immunodeficiency virus infection: an echocardiographic study of 157 patients in hospital in Zimbabwe. Heart 1996; 76 (2) 161-165
• 92 Olusegun-Joseph DA, Ajuluchukwu JN, Okany CC, Mbakwem AC, Oke DA, Okubadejo NU. Echocardiographic patterns in treatment-naïve HIV-positive patients in Lagos, south-west Nigeria. Cardiovasc J Afr 2012; 23 (8) e1-e6
• 93 Jain N, Reddy DH, Verma SP , et al. Cardiac abnormalities in HIV-positive patients: results from an observational study in India. J Int Assoc Provid AIDS Care 2014; 13 (1) 40-46
• 94 Luo L, Zeng Y, Li T , et al; China AIDS Clinical Trial 0810 Group. Prospective echocardiographic assessment of cardiac structure and function in Chinese persons living with HIV. Clin Infect Dis 2014; 58 (10) 1459-1466
• 95 Ntsekhe M, Mayosi BM. Cardiac manifestations of HIV infection: an African perspective. Nat Clin Pract Cardiovasc Med 2009; 6 (2) 120-127
• 96 Stein L, Urban MI, O'Connell D , et al. The spectrum of human immunodeficiency virus-associated cancers in a South African black population: results from a case-control study, 1995-2004. Int J Cancer 2008; 122 (10) 2260-2265
• 97 Hou W, Fu J, Ge Y, Du J, Hua S. Incidence and risk of lung cancer in HIV-infected patients. J Cancer Res Clin Oncol 2013; 139 (11) 1781-1794
• 98 Mbulaiteye SM, Katabira ET, Wabinga H , et al. Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer Registry Match Study. Int J Cancer 2006; 118 (4) 985-990
• 99 Pinto Neto LF, Milanez MdaC, Golub JE, Miranda AE. Malignancies in HIV/AIDS patients attending an outpatient clinic in Vitória, State of Espírito Santo, Brazil. Rev Soc Bras Med Trop 2012; 45 (6) 687-690
• 100 Fitzmaurice C, Dicker D, Pain A , et al; Global Burden of Disease Cancer Collaboration. The Global Burden of Cancer 2013. JAMA Oncol 2015; 1 (4) 505-527
• 101 Winstone TA, Man SF, Hull M, Montaner JS, Sin DD. Epidemic of lung cancer in patients with HIV infection. Chest 2013; 143 (2) 305-314
• 102 Hirschhorn LR, Kaaya SF, Garrity PS, Chopyak E, Fawzi MC. Cancer and the ‘other’ noncommunicable chronic diseases in older people living with HIV/AIDS in resource-limited settings: a challenge to success. AIDS 2012; 26 (Suppl. 01) S65-S75
• 103 Casper C. The increasing burden of HIV-associated malignancies in resource-limited regions. Annu Rev Med 2011; 62: 157-170
• 104 Timblin C, BeruBe K, Churg A , et al. Ambient particulate matter causes activation of the c-jun kinase/stress-activated protein kinase cascade and DNA synthesis in lung epithelial cells. Cancer Res 1998; 58 (20) 4543-4547
• 105 Prendergast AJ, Essajee S, Penazzato M. HIV and the Millennium Development Goals. Arch Dis Child 2015; 100 (Suppl. 01) S48-S52
• 106 Danel C, Moh R, Gabillard D , et al; TEMPRANO ANRS 12136 Study Group. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med 2015; 373 (9) 808-822
• 107 Lundgren JD, Babiker AG, Gordin F , et al; INSIGHT START Study Group. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med 2015; 373 (9) 795-807
• 108 Munro SA, Lewin SA, Smith HJ, Engel ME, Fretheim A, Volmink J. Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med 2007; 4 (7) e238
• 109 Sabaté E. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Swizerland: World Health Organization; 2003
• 110 Mitiku H, Weldegebreal F, Teklemariam Z. Magnitude of opportunistic infections and associated factors in HIV-infected adults on antiretroviral therapy in eastern Ethiopia. HIV AIDS (Auckl) 2015; 7: 137-144
• 111 Rubaihayo J, Tumwesigye NM, Konde-Lule J. Trends in prevalence of selected opportunistic infections associated with HIV/AIDS in Uganda. BMC Infect Dis 2015; 15: 187
• 112 Prentice AM, Moore SE. Early programming of adult diseases in resource poor countries. Arch Dis Child 2005; 90 (4) 429-432
• 113 Hemkens LG, Bucher HC. HIV infection and cardiovascular disease. Eur Heart J 2014; 35 (21) 1373-1381
• 114 Stern DA, Morgan WJ, Wright AL, Guerra S, Martinez FD. Poor airway function in early infancy and lung function by age 22 years: a non-selective longitudinal cohort study. Lancet 2007; 370 (9589) 758-764
• 115 Bisgaard H, Jensen SM, Bønnelykke K. Interaction between asthma and lung function growth in early life. Am J Respir Crit Care Med 2012; 185 (11) 1183-1189
• 116 Stocks J, Sonnappa S. Early life influences on the development of chronic obstructive pulmonary disease. Ther Adv Respir Dis 2013; 7 (3) 161-173
• 117 Black RE, Allen LH, Bhutta ZA , et al; Maternal and Child Undernutrition Study Group. Maternal and child undernutrition: global and regional exposures and health consequences. Lancet 2008; 371 (9608) 243-260
• 118 Irlam JH, Visser MM, Rollins NN, Siegfried N. Micronutrient supplementation in children and adults with HIV infection. Cochrane Database Syst Rev 2010; (12) CD003650
• 119 Bobat R, Coovadia H, Stephen C , et al. Safety and efficacy of zinc supplementation for children with HIV-1 infection in South Africa: a randomised double-blind placebo-controlled trial. Lancet 2005; 366 (9500) 1862-1867
• 120 Lim SS, Vos T, Flaxman AD , et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380 (9859) 2224-2260
• 121 Kurmi OP, Semple S, Simkhada P, Smith WC, Ayres JG. COPD and chronic bronchitis risk of indoor air pollution from solid fuel: a systematic review and meta-analysis. Thorax 2010; 65 (3) 221-228
• 122 Sumpter C, Chandramohan D. Systematic review and meta-analysis of the associations between indoor air pollution and tuberculosis. Trop Med Int Health 2013; 18 (1) 101-108
• 123 van Zyl Smit RN, Pai M, Yew WW , et al. Global lung health: the colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD. Eur Respir J 2010; 35 (1) 27-33
• 124 Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet 2013; 382 (9903) 1525-1533
• 125 Crothers K, Thompson BW, Burkhardt K , et al; Lung HIV Study. HIV-associated lung infections and complications in the era of combination antiretroviral therapy. Proc Am Thorac Soc 2011; 8 (3) 275-281
• 126 Remais JV, Zeng G, Li G, Tian L, Engelgau MM. Convergence of non-communicable and infectious diseases in low- and middle-income countries. Int J Epidemiol 2013; 42 (1) 221-227
• 127 Harpham T. Urban health in developing countries: what do we know and where do we go?. Health Place 2009; 15 (1) 107-116
• 128 Lienhardt C, Fielding K, Sillah J , et al. Risk factors for tuberculosis infection in sub-Saharan Africa: a contact study in The Gambia. Am J Respir Crit Care Med 2003; 168 (4) 448-455
• 129 Coker R, McKee M, Atun R , et al. Risk factors for pulmonary tuberculosis in Russia: case-control study. BMJ 2006; 332 (7533) 85-87
• 130 Greer A, Ng V, Fisman D. Climate change and infectious diseases in North America: the road ahead. CMAJ 2008; 178 (6) 715-722
• 131 Patel P, Hanson DL, Sullivan PS , et al; Adult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigators. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148 (10) 728-736
• 132 Helleberg M, Afzal S, Kronborg G , et al. Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis 2013; 56 (5) 727-734
• 133 Jackson-Morris A, Latif E. Strengthening government tobacco control in low- and middle-income countries: a ‘must do’ for lung health progress. Int J Tuberc Lung Dis 2013; 17 (8) 997-1000
• 134 Suthar AB, Granich R, Mermin J, Van Rie A. Effect of cotrimoxazole on mortality in HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis. Bull World Health Organ 2012; 90 (2) 128C-138C
• 135 Grimwade K, Swingler GH. Cotrimoxazole prophylaxis for opportunistic infections in children with HIV infection. Cochrane Database Syst Rev 2006; (1) CD003508
• 136 Dworkin MS, Williamson J, Jones JL, Kaplan JE ; Adult and Adolescent Spectrum of HIV Disease Project. Prophylaxis with trimethoprim-sulfamethoxazole for human immunodeficiency virus-infected patients: impact on risk for infectious diseases. Clin Infect Dis 2001; 33 (3) 393-398
• 137 Anglaret X, Chêne G, Attia A , et al; Cotrimo-CI Study Group. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Lancet 1999; 353 (9163) 1463-1468
• 138 Mermin J, Lule J, Ekwaru JP , et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004; 364 (9443) 1428-1434
• 139 Chintu C, Bhat GJ, Walker AS , et al; CHAP trial team. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet 2004; 364 (9448) 1865-1871
• 140 WHO. Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV related infections among adults, adolescents and children: recommendations for a public health approach. 2013. Available at: http://www.who.int/hiv/pub/guidelines/arv2013/arvs2013upplement_dec2014/en/ . Accessed February 06, 2016
• 141 Mocroft A, Reiss P, Kirk O , et al; Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE). Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?. Clin Infect Dis 2010; 51 (5) 611-619
• 142 Church JA, Fitzgerald F, Walker AS, Gibb DM, Prendergast AJ. The expanding role of co-trimoxazole in developing countries. Lancet Infect Dis 2015; 15 (3) 327-339
• 143 Bwakura-Dangarembizi M, Kendall L, Bakeera-Kitaka S , et al; Antiretroviral Research for Watoto (ARROW) Trial Team. A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa. N Engl J Med 2014; 370 (1) 41-53
• 144 Date AA, Vitoria M, Granich R, Banda M, Fox MY, Gilks C. Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV. Bull World Health Organ 2010; 88 (4) 253-259
• 145 Zachariah R, Harries AD, Luo C, Bachman G, Graham SM. Scaling-up co-trimoxazole prophylaxis in HIV-exposed and HIV-infected children in high HIV-prevalence countries. Lancet Infect Dis 2007; 7 (10) 686-693
• 146 Moodley D, Reddy L, Mahungo W, Masha R. Factors associated with coverage of cotrimoxazole prophylaxis in HIV-exposed children in South Africa. PLoS ONE 2013; 8 (5) e63273
• 147 Pope III CA. Respiratory hospital admissions associated with PM10 pollution in Utah, Salt Lake, and Cache Valleys. Arch Environ Health 1991; 46 (2) 90-97
• 148 Briggs MA, Emerson C, Modi S, Taylor NK, Date A. Use of isoniazid preventive therapy for tuberculosis prophylaxis among people living with HIV/AIDS: a review of the literature. J Acquir Immune Defic Syndr 2015; 68 (Suppl. 03) S297-S305
• 149 Aït-Khaled N, Alarcon E, Bissell K , et al. Isoniazid preventive therapy for people living with HIV: public health challenges and implementation issues. Int J Tuberc Lung Dis 2009; 13 (8) 927-935
• 150 Kroon FP, van Dissel JT, de Jong JC, van Furth R. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS 1994; 8 (4) 469-476
• 151 Huang KL, Ruben FL, Rinaldo Jr CR, Kingsley L, Lyter DW, Ho M. Antibody responses after influenza and pneumococcal immunization in HIV-infected homosexual men. JAMA 1987; 257 (15) 2047-2050
• 152 Janoff EN, Douglas Jr JM, Gabriel M , et al. Class-specific antibody response to pneumococcal capsular polysaccharides in men infected with human immunodeficiency virus type 1. J Infect Dis 1988; 158 (5) 983-990
• 153 Amendola A, Tanzi E, Zappa A , et al. Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-1 infected former drug users. Vaccine 2002; 20 (31-32) 3720-3724
• 154 Janoff EN, Fasching C, Ojoo JC, O'Brien J, Gilks CF. Responsiveness of human immunodeficiency virus type 1-infected Kenyan women with or without prior pneumococcal disease to pneumococcal vaccine. J Infect Dis 1997; 175 (4) 975-978
• 155 Opravil M, Fierz W, Matter L, Blaser J, Lüthy R. Poor antibody response after tetanus and pneumococcal vaccination in immunocompromised, HIV-infected patients. Clin Exp Immunol 1991; 84 (2) 185-189
• 156 Rodriguez-Barradas MC, Alexandraki I, Nazir T , et al. Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine. Clin Infect Dis 2003; 37 (3) 438-447
• 157 Tasker SA, Wallace MR, Rubins JB, Paxton WB, O'Brien J, Janoff EN. Reimmunization with 23-valent pneumococcal vaccine for patients infected with human immunodeficiency virus type 1: clinical, immunologic, and virologic responses. Clin Infect Dis 2002; 34 (6) 813-821
• 158 Bliss SJ, O'Brien KL, Janoff EN , et al. The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease. Lancet Infect Dis 2008; 8 (1) 67-80
• 159 French N, Nakiyingi J, Carpenter LM , et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000; 355 (9221) 2106-2111
• 160 French N, Gordon SB, Mwalukomo T , et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010; 362 (9) 812-822
• 161 Lesprit P, Pédrono G, Molina JM , et al; ANRS 114-Pneumovac Study Group. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS 2007; 21 (18) 2425-2434
• 162 Madhi SA, Petersen K, Khoosal M , et al. Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection. Pediatr Infect Dis J 2002; 21 (4) 315-321
• 163 Dockrell DH, Poland GA, Steckelberg JM, Wollan PC, Strickland SR, Pomeroy C. Immunogenicity of three Haemophilus influenzae type b protein conjugate vaccines in HIV seropositive adults and analysis of predictors of vaccine response. Vaccine 1999; 17 (22) 2779-2785
• 164 Steinhoff MC, Auerbach BS, Nelson KE , et al. Antibody responses to Haemophilus influenzae type B vaccines in men with human immunodeficiency virus infection. N Engl J Med 1991; 325 (26) 1837-1842
• 165 De Sousa dos Santos S, Lopes MH, Simonsen V, Caiaffa Filho HH. Haemophilus influenzae type b immunization in adults infected with the human immunodeficiency virus. AIDS Res Hum Retroviruses 2004; 20 (5) 493-496
• 166 Remschmidt C, Wichmann O, Harder T. Influenza vaccination in HIV-infected individuals: systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness and safety. Vaccine 2014; 32 (43) 5585-5592
• 167 WHO. Immunization Summary: A Statistical Reference Containing Data through 2013. Geneva, Switzerland: WHO; 2013. Available at: http://www.who.int/immunization/monitoring_surveillance/Immunization_Summary_2013.pdf . Accessed February 06, 2016
• 168 WHO. Effective vaccine management (EVM) report 2014. Available at: http://www.who.int/immunization/sage/meetings/2014/april/2_EVM_JS_DraftStatement_5.2.pdf . Accessed February 06, 2016
• 169 Vaccine goal indicators 2015. Available at: http://www.gavi.org/results/goal-level-indicators/vaccine-goal-indicators/ . Accessed August 27, 2015
• 170 Ducel G, Fabry J, Nicolle L. Prevention of hospital acquired infections: a practical guide 2002. Available at: http://www.who.int/iris/handle/10665/67350#sthash.ssuingP2.dpuf . Accessed February 06, 2016
• 171 Basu S, Andrews JR, Poolman EM , et al. Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study. Lancet 2007; 370 (9597) 1500-1507
• 172 Raka L. Prevention and Control of Hospital-Related Infections in Low and Middle Income Countries. Open Infectious Disease Journal 2010; 4 (1) 125-131
• 173 Schmitz K, Kempker RR, Tenna A , et al. Effectiveness of a multimodal hand hygiene campaign and obstacles to success in Addis Ababa, Ethiopia. Antimicrob Resist Infect Control 2014; 3 (1) 8
• 174 Benito N, Rañó A, Moreno A , et al. Pulmonary infiltrates in HIV-infected patients in the highly active antiretroviral therapy era in Spain. J Acquir Immune Defic Syndr 2001; 27 (1) 35-43
• 175 de Armas Rodríguez Y, Wissmann G, Müller AL , et al. Pneumocystis jirovecii pneumonia in developing countries. Parasite 2011; 18 (3) 219-228
• 176 Antinori S. Histoplasma capsulatum: more widespread than previously thought. Am J Trop Med Hyg 2014; 90 (6) 982-983
• 177 Clark RA, Greer DL, Valainis GT, Hyslop NE. Cryptococcus neoformans pulmonary infection in HIV-1-infected patients. J Acquir Immune Defic Syndr 1990; 3 (5) 480-484
• 178 Visnegarwala F, Graviss EA, Lacke CE , et al. Acute respiratory failure associated with cryptococcosis in patients with AIDS: analysis of predictive factors. Clin Infect Dis 1998; 27 (5) 1231-1237
• 179 Pai M, Schito M. Tuberculosis diagnostics in 2015: landscape, priorities, needs, and prospects. J Infect Dis 2015; 211 (Suppl. 02) S21-S28
• 180 Havlir DV, Getahun H, Sanne I, Nunn P. Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA 2008; 300 (4) 423-430
• 181 Qin ZZ, Pai M, Van Gemert W, Sahu S, Ghiasi M, Creswell J. How is Xpert MTB/RIF being implemented in 22 high tuberculosis burden countries?. Eur Respir J 2015; 45 (2) 549-554
• 182 Churchyard GJ, Stevens WS, Mametja LD , et al. Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF. Lancet Glob Health 2015; 3 (8) e450-e457
• 183 Gingo MR, Wenzel SE, Steele C , et al. Asthma diagnosis and airway bronchodilator response in HIV-infected patients. J Allergy Clin Immunol 2012; 129 (3) 708-714.e8
• 184 Finney LJ, Feary JR, Leonardi-Bee J, Gordon SB, Mortimer K. Chronic obstructive pulmonary disease in sub-Saharan Africa: a systematic review. Int J Tuberc Lung Dis 2013; 17 (5) 583-589
• 185 Angthong W, Angthong C, Varavithya V. Pretreatment and posttreatment radiography in patients with pulmonary tuberculosis with and without human immunodeficiency virus infection. Jpn J Radiol 2011; 29 (8) 554-562
• 186 Báez-Saldaña R, López-Arteaga Y, Bizarrón-Muro A , et al. A novel scoring system to measure radiographic abnormalities and related spirometric values in cured pulmonary tuberculosis. PLoS ONE 2013; 8 (11) e78926
• 187 WHO. Guidelines for the Clinical Management of HIV Infection in Adult. Geneva, Switzerland: WHO; 1991
• 188 Lynen L. Treatment and Prevention of Opportunistic Infections at the Level of Referral Hospital in Resource-Limited Settings. Luxembourg: MSF Belgium; 2005
• 189 Mukabatsinda C, Nguyen J, Bisig B , et al. Is increasing complexity of algorithms the price for higher accuracy? virtual comparison of three algorithms for tertiary level management of chronic cough in people living with HIV in a low-income country. BMC Med Inform Decis Mak 2012; 12: 2
• 190 Schneider A, Gindner L, Tilemann L , et al. Diagnostic accuracy of spirometry in primary care. BMC Pulm Med 2009; 9: 31
• 191 Woolcock AJ. What are the important questions in the treatment of asthma. Clin Exp Allergy Rev 2001; 1 (2) 62-64
• 192 WHO. Acute Care - Integrated Management of Adolescent and Adult Illness. Geneva, Switzerland: WHO; 2009
• 193 Gove S, Tamburlini G, Molyneux E, Whitesell P, Campbell H. Development and technical basis of simplified guidelines for emergency triage assessment and treatment in developing countries. WHO Integrated Management of Childhood Illness (IMCI) Referral Care Project. Arch Dis Child 1999; 81 (6) 473-477
• 194 Okeke IN, Lamikanra A, Edelman R. Socioeconomic and behavioral factors leading to acquired bacterial resistance to antibiotics in developing countries. Emerg Infect Dis 1999; 5 (1) 18-27
• 195 Kariuki S, Dougan G. Antibacterial resistance in sub-Saharan Africa: an underestimated emergency. Ann N Y Acad Sci 2014; 1323: 43-55
• 196 WHO model list of essential medications 2015. Available at: http://www.who.int/medicines/publications/essentialmedicines/en/ . Accessed September 21, 2015
• 197 Wheat LJ, Freifeld AG, Kleiman MB , et al; Infectious Diseases Society of America. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45 (7) 807-825
• 198 Day JN, Chau TT, Wolbers M , et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med 2013; 368 (14) 1291-1302
• 199 Govender NP, Meintjes G, Banoo S. Access to flucytosine for HIV-infected patients with cryptococcal meningitis – an urgent need. S Afr Med J 2014; 104 (9) 594-595
• 200 Gnatiuc L, Buist AS, Kato B , et al; BOLD Collaboration. Gaps in using bronchodilators, inhaled corticosteroids and influenza vaccine among 23 high- and low-income sites. Int J Tuberc Lung Dis 2015; 19 (1) 21-30
• 201 Hammelin V. The role of physiotherapists in global health. Glob J Med Public Health 2014; 3 (4) 1-2
• 202 Baker T. Critical care in low-income countries. Trop Med Int Health 2009; 14 (2) 143-148
• 203 Evans HT, Mahmood N, Fullerton DG , et al. Oxygen saturations of medical inpatients in a Malawian hospital: cross-sectional study of oxygen supply and demand. Pneumonia 2012; 1: 3-6 ; Available at: https://pneumonia.org.au/index.php/pneumonia/article/view/208 . Accessed February 06, 2016
• 204 Bradley BD, Howie SR, Chan TC, Cheng YL. Estimating oxygen needs for childhood pneumonia in developing country health systems: a new model for expecting the unexpected. PLoS ONE 2014; 9 (2) e89872
• 205 Krishnamoorthy V, Vavilala MS, Mock CN. The need for ventilators in the developing world: An opportunity to improve care and save lives. J Glob Health 2014; 4 (1) 010303
• 206 Murthy S, Adhikari NK. Global health care of the critically ill in low-resource settings. Ann Am Thorac Soc 2013; 10 (5) 509-513
• 207 Baker T, Lugazia E, Eriksen J, Mwafongo V, Irestedt L, Konrad D. Emergency and critical care services in Tanzania: a survey of ten hospitals. BMC Health Serv Res 2013; 13: 140
• 208 Beck JM, Schloss PD, Venkataraman A , et al; Lung HIV Microbiome Project. Multicenter Comparison of Lung and Oral Microbiomes of HIV-infected and HIV-uninfected Individuals. Am J Respir Crit Care Med 2015; 192 (11) 1335-1344
• 209 ClinicalTrials.gov. Bronchopulmonary function in response to azithromycin treatment for chronic lung disease in HIV-infected children (BREATHE). 2015 ; ClinicalTrials.gov Identifier: NCT02426112. Available at: https://clinicaltrials.gov/ct2/show/NCT02426112 . Accessed February 06, 2016